ERBB2 and ovarian carcinoma: Here, the Fab’ derived from Trastuzumab (TRZ), a clinically approved recombinant humanized mAb,[14] was selected to target with high affinity its antigen, the human epidermal growth factor receptor 2 (HER2)[15] which is overexpressed in 20–30% of invasive breast and ovarian carcinomas.[16] We investigated the advantage of targeted immunoliposomes, obtained by decorating the surface of liposomes with Fab’ moieties coupled to a PEG spacer bearing a phospholipid moiety for the anchoring to the phospholipid bilayer (Figure 1A).